RA Capital Management’s Entera Bio ENTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$14.3M Buy
+4,901,960
New +$13.1M 0.14% 68
2023
Q2
– Sell
-295,966
Closed -$343K – 56
2023
Q1
$343K Hold
295,966
– – 0.01% 59
2022
Q4
$216K Sell
295,966
-1,786,406
-86% -$1.29M ﹤0.01% 70
2022
Q3
$2.17M Sell
2,082,372
-270,628
-12% -$408K 0.05% 75
2022
Q2
$3.13M Hold
2,353,000
– – 0.08% 75
2022
Q1
$6.75M Hold
2,353,000
– – 0.15% 86
2021
Q4
$6.62M Hold
2,353,000
– – 0.12% 90
2021
Q3
$11.1M Hold
2,353,000
– – 0.15% 72
2021
Q2
$14.1M Buy
+2,353,000
New +$8.7M 0.23% 63

Other funds holding ENTX

RA Capital Management's ENTX Position: Q3 2026 in Review

RA Capital Management opened a new position in Entera Bio (ENTX) in Q3 2026: 4,901,960 shares worth $14.3M. The stake represents 0.14% of the portfolio and ranks #68 among its holdings. This is a return to the name: RA Capital Management previously reported a position in ENTX as recently as Q1 2023.

RA Capital Management first reported a position in ENTX in Q2 2021 and has held it in 9 quarters since. 46 funds tracked by Wall St. Rank hold ENTX as of Q3 2026.

  • RA Capital Management held 4,901,960 shares of Entera Bio worth $14.3M as of Q3 2026.
  • Entera Bio was a new RA Capital Management position in Q3 2026.
  • Entera Bio made up 0.14% of RA Capital Management's portfolio in Q3 2026, its #68 holding.
  • RA Capital Management first reported a position in Entera Bio in Q2 2021 and has held it in 9 quarters since.
  • 46 funds tracked by Wall St. Rank held Entera Bio as of Q3 2026.

Based on RA Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.